Guggenheim Capital’s Alder Biopharmaceuticals ALDR Stock Holding History

Guggenheim Capital’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-19,973	Closed	-$245K	–	2875
2017 Q3	$245K	Sell	19,973 -89,583	-82%	-$934K	﹤0.01%	2581
2017 Q2	$1.25M	Buy	109,556 +14,831	+16%	+$274K	﹤0.01%	1939
2017 Q1	$1.97M	Buy	94,725 +4,745	+5%	+$105K	0.01%	1674
2016 Q4	$1.87M	Buy	89,980 +7,472	+9%	+$194K	0.01%	1739
2016 Q3	$2.7M	Sell	82,508 -8,210	-9%	-$250K	0.01%	1412
2016 Q2	$2.27M	Sell	90,718 -19,253	-18%	-$521K	0.01%	1487
2016 Q1	$2.69M	Buy	109,971 +52,784	+92%	+$1.22M	0.01%	1365
2015 Q4	$1.89M	Buy	57,187 +6,028	+12%	+$204K	0.01%	1655
2015 Q3	$1.68M	Buy	+51,159	New	+$2.17M	0.01%	1727

Other funds holding ALDR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Guggenheim Capital's ALDR Position: Q4 2017 in Review

Guggenheim Capital sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 19,973 shares — an estimated $245K sold.

Guggenheim Capital first reported a position in ALDR in Q3 2015 and held it in 9 quarters. The position peaked at $2.7M in Q3 2016. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

Guggenheim Capital reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
Guggenheim Capital sold 19,973 Alder Biopharmaceuticals shares in Q4 2017, an estimated $245K.
Guggenheim Capital first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 9 quarters.
Guggenheim Capital's Alder Biopharmaceuticals position peaked at $2.7M in Q3 2016.
140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Guggenheim Capital's 13F filing for Q4 2017, filed 14 Feb 2018.